Somatic mutations in genes encoding the enzymes IDH1 and IDH2 have been identified through genome-wide sequencing studies in approximately 70% of grade II and III gliomas, and in approximately 5% of GBMs [3,4], (for a review see [5]). This evidence concerns the gene IDH1 and central nervous system cancer.